High throughput screening for inhibitors of the HECT ubiquitin E3 ligase ITCH identifies antidepressant drugs as regulators of autophagy

Cell Death and Disease

Volumn 5, Issue 5, 2014, Pages

  Rossi, M ^a,b   Rotblat, B ^a   Ansell, K ^c   Amelio, I ^a   Caraglia, M ^d   Misso, G ^d   Bernassola, F ^e   Cavasotto, C N ^b   Knight, R A ^a   Ciechanover, A ^f   Melino, G ^a,e  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

^b Facultad de Ciencias Naturales e Instituto M Lillo   (Argentina)

^c MEDICAL RESEARCH COUNCIL   (United Kingdom)

^d SECOND UNIVERSITY OF NAPLES   (Italy)

^e UNIVERSITY OF ROME TOR VERGATA   (Italy)

^f TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

Antidepressant; Autophagy; E3 ligase; HECT; Inhibitors; Ubiquitin

Indexed keywords

ANTIDEPRESSANT AGENT; ANTINEOPLASTIC AGENT; CLOMIPRAMINE; GEMCITABINE; HT 1376; ITCH PROTEIN; LIGASE INHIBITOR; MITOMYCIN; NORCLOMIPRAMINE; PROTEIN P73; UBIQUITIN PROTEIN LIGASE E3; UNCLASSIFIED DRUG; ENZYME INHIBITOR; UBIQUITIN; UBIQUITIN PROTEIN LIGASE;

ARTICLE; AUTOPHAGOSOME; AUTOPHAGY; BLADDER CANCER CELL LINE; BREAST CANCER CELL LINE; CANCER GROWTH; CANCER INHIBITION; CELL DEATH; CELL GROWTH; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; IN VITRO STUDY; PRIORITY JOURNAL; PROSTATE CANCER CELL LINE; UBIQUITINATION; WESTERN BLOTTING; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; BINDING SITE; CHEMICAL STRUCTURE; CHEMISTRY; DRUG EFFECTS; DRUG POTENTIATION; METABOLISM; PROCEDURES; PROTEIN TERTIARY STRUCTURE; REPRODUCIBILITY; TUMOR CELL LINE;

ANTIDEPRESSIVE AGENTS; AUTOPHAGY; BINDING SITES; CELL LINE, TUMOR; CLOMIPRAMINE; DRUG SYNERGISM; ENZYME INHIBITORS; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; MODELS, MOLECULAR; PROTEIN STRUCTURE, TERTIARY; REPRODUCIBILITY OF RESULTS; UBIQUITIN; UBIQUITIN-PROTEIN LIGASES;

EID: 84901048406     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2014.113     Document Type: Article

References (60)

1. Ciechanover A. Intracellular protein degradation: from a vague idea thru the lysosome and the ubiquitin-proteasome system and onto human diseases and drug targeting. Cell Death Differ 2005; 12: 1178-1190.
2. Hershko A. The ubiquitin system for protein degradation and some of its roles in the control of the cell division cycle. Cell Death Differ 2005; 12: 1191-1197.
3. Melino G. Discovery of the ubiquitin proteasome system and its involvement in apoptosis. Cell Death Differ 2005; 12: 1155-1157.
4. Ciechanover A. The ubiquitin-proteasome proteolytic pathway. Cell 1994; 79: 13-21.
5. Pickart CM. Mechanisms underlying ubiquitination. Annu Rev Biochem 2001; 70: 503-533.
6. Bernassola F, Karin M, Ciechanover A, Melino G. The HECT family of E3 ubiquitin ligases: multiple players in cancer development. Cancer cell 2008; 14: 10-21.
7. Raimondo D, Giorgetti A, Bernassola F, Melino G, Tramontano A. Modeling and molecular dynamics of the interaction between the E3 ubiquitin ligase Itch and the E2 UbcH7. Biochem Pharmacol 2008; 76: 1620-1627.
8. Scialpi F, Malatesta M, Peschiaroli A, Rossi M, Melino G, Bernassola F. Itch self-polyubiquitylation occurs through lysine-63 linkages. Biochem Pharmacol 2008; 76: 1515-1521.
9. Perry WL, Hustad CM, Swing DA, O'Sullivan TN, Jenkins NA, Copeland NG. The itchy locus encodes a novel ubiquitin protein ligase that is disrupted in a18H mice. Nat Genet 1998; 18: 143-146.
10. Maisse C, Guerrieri P, Melino G. p73 and p63 protein stability: the way to regulate function? Biochem Pharmacol 2003; 66: 1555-1561.
11. Rossi M, De Laurenzi V, Munarriz E, Green DR, Liu YC, Vousden KH et al. The ubiquitinprotein ligase Itch regulates p73 stability. EMBO J 2005; 24: 836-848.
12. Rossi M, Aqeilan RI, Neale M, Candi E, Salomoni P, Knight RA et al. The E3 ubiquitin ligase Itch controls the protein stability of p63. Proc Natl Acad Sci USA 2006; 103: 12753-12758.
13. Melino G, Knight RA, Cesareni G. Degradation of p63 by Itch. Cell Cycle 2006; 5: 1735-1739.
14. Bellomaria A, Barbato G, Melino G, Paci M, Melino S. Recognition of p63 by the E3 ligase ITCH: effect of an ectodermal dysplasia mutant. Cell Cycle 2010; 9: 3730-3739.
15. Browne G, Cipollone R, Lena AM, Serra V, Zhou H, van Bokhoven H et al. Differential altered stability and transcriptional activity of DeltaNp63 mutants in distinct ectodermal dysplasias. J Cell Sci 2011; 124(Pt 13): 2200-2207.
16. Bellomaria A, Barbato G, Melino G, Paci M, Melino S. Recognition mechanism of p63 by the E3 ligase Itch: novel strategy in the study and inhibition of this interaction. Cell Cycle 2012; 11: 3638-3648.
17. Salah Z, Melino G, Aqeilan RI. Negative regulation of the Hippo pathway by E3 ubiquitin ligase ITCH is sufficient to promote tumorigenicity. Cancer Res 2011; 71: 2010-2020.
18. Chang L, Kamata H, Solinas G, Luo JL, Maeda S, Venuprasad K et al. The E3 ubiquitin ligase itch couples JNK activation to TNFalpha-induced cell death by inducing c-FLIP(L) turnover. Cell 2006; 124: 601-613.
19. Zhang P, Wang C, Gao K, Wang D, Mao J, An J et al. The ubiquitin ligase itch regulates apoptosis by targeting thioredoxin-interacting protein for ubiquitin-dependent degradation. J Biol Chem 2010; 285: 8869-8879.
20. Azakir BA, Desrochers G, Angers A. The ubiquitin ligase Itch mediates the antiapoptotic activity of epidermal growth factor by promoting the ubiquitylation and degradation of the truncated C-terminal portion of Bid. FEBS J 2010; 277: 1319-1330.
21. Suryaraja R, Anitha M, Anbarasu K, Kumari G, Mahalingam S. The E3 ubiquitin ligase Itch regulates tumor suppressor protein RASSF5/NORE1 stability in an acetylation-dependent manner. Cell Death Dis 2013; 4: e565.
22. Ho KC, Zhou Z, She YM, Chun A, Cyr TD, Yang X. Itch E3 ubiquitin ligase regulates large tumor suppressor 1 stability [corrected]. Proc Natl Acad Sci USA 2011; 108: 4870-4875.
23. Ishihara T, Inoue J, Kozaki K, Imoto I, Inazawa J. HECT-type ubiquitin ligase ITCH targets lysosomal-associated protein multispanning transmembrane 5 (LAPTM5) and prevents LAPTM5-mediated cell death. J Biol Chem 2011; 286: 44086-44094.
24. Sundvall M, Korhonen A, Paatero I, Gaudio E, Melino G, Croce CM et al. Isoform-specific monoubiquitination, endocytosis, and degradation of alternatively spliced ErbB4 isoforms. Proc Natl Acad Sci USA 2008; 105: 4162-4167.
25. Fang D, Elly C, Gao B, Fang N, Altman Y, Joazeiro C et al. Dysregulation of T lymphocyte function in itchy mice: a role for Itch in TH2 differentiation. Nat Immunol 2002; 3: 281-287.
26. Heissmeyer V, Macian F, Im SH, Varma R, Feske S, Venuprasad K et al. Calcineurin imposes T cell unresponsiveness through targeted proteolysis of signaling proteins. Nat Immunol 2004; 5: 255-265.
27. Venuprasad K, Elly C, Gao M, Salek-Ardakani S, Harada Y, Luo JL et al. Convergence of Itch-induced ubiquitination with MEKK1-JNK signaling in Th2 tolerance and airway inflammation. J Clin Invest 2006; 116: 1117-1126.
28. Shembade N, Harhaj NS, Parvatiyar K, Copeland NG, Jenkins NA, Matesic LE et al. The E3 ligase Itch negatively regulates inflammatory signaling pathways by controlling the function of the ubiquitin-editing enzyme A20. Nat Immunol 2008; 9: 254-262.
29. Qiu L, Joazeiro C, Fang N, Wang HY, Elly C, Altman Y et al. Recognition and ubiquitination of Notch by Itch, a hect-type E3 ubiquitin ligase. J Biol Chem 2000; 275: 35734-35737.
30. Bai Y, Yang C, Hu K, Elly C, Liu YC. Itch E3 ligase-mediated regulation of TGF-beta signaling by modulating smad2 phosphorylation. Mol Cell 2004; 15: 825-831.
31. Venuprasad K, Huang H, Harada Y, Elly C, Subramaniam M, Spelsberg T et al. The E3 ubiquitin ligase Itch regulates expression of transcription factor Foxp3 and airway inflammation by enhancing the function of transcription factor TIEG1. Nat Immunol 2008; 9: 245-253.
32. Marchese A, Raiborg C, Santini F, Keen JH, Stenmark H, Benovic JL. The E3 ubiquitin ligase AIP4 mediates ubiquitination and sorting of the G protein-coupled receptor CXCR4. Dev Cell 2003; 5: 709-722.
33. Rivetti di Val Cervo P, Tucci P, Majid A, Lena AM, Agostini M, Bernardini S et al. p73, miR106b, miR34a, and Itch in chronic lymphocytic leukemia. Blood 2009; 113: 6498-6499; author reply 9-500.
34. Rossi M, Inoue S, Walewska R, Knight RA, Dyer MJ, Cohen GM et al. Caspase cleavage of Itch in chronic lymphocytic leukemia cells. Biochem Biophys Res Commun 2009; 379: 659-664.
35. Hansen TM, Rossi M, Roperch JP, Ansell K, Simpson K, Taylor D et al. Itch inhibition regulates chemosensitivity in vitro. Biochem Biophys Res Commun 2007; 361: 33-36.
36. Ishihara T, Tsuda H, Hotta A, Kozaki K, Yoshida A, Noh JY et al. ITCH is a putative target for a novel 20q11.22 amplification detected in anaplastic thyroid carcinoma cells by array-based comparative genomic hybridization. Cancer Sci 2008; 99: 1940-1949.
37. Oberst A, Malatesta M, Aqeilan RI, Rossi M, Salomoni P, Murillas R et al. The Nedd4- binding partner 1 (N4BP1) protein is an inhibitor of the E3 ligase Itch. Proc Natl Acad Sci USA 2007; 104: 11280-11285.
38. Zaaroor-Regev D, de Bie P, Scheffner M, Noy T, Shemer R, Heled M et al. Regulation of the polycomb protein Ring1B by self-ubiquitination or by E6-AP may have implications to the pathogenesis of Angelman syndrome. Proc Natl Acad Sci USA 2010; 107: 6788-6793.
39. Herman-Bachinsky Y, Ryoo HD, Ciechanover A, Gonen H. Regulation of the Drosophila ubiquitin ligase DIAP1 is mediated via several distinct ubiquitin system pathways. Cell Death Differ 2007; 14: 861-871.
40. Rossi M, Munarriz ER, Bartesaghi S, Milanese M, Dinsdale D, Guerra-Martin MA et al. Desmethylclomipramine induces the accumulation of autophagy markers by blocking autophagic flux. J Cell Sci 2009; 122(Pt 18): 3330-3339.
41. White E, DiPaola RS. The double-edged sword of autophagy modulation in cancer. Clin Cancer Res 2009; 15: 5308-5316.
42. Munafo DB, Colombo MI. A novel assay to study autophagy: regulation of autophagosome vacuole size by amino acid deprivation. J Cell Sci 2001; 114(Pt 20): 3619-3629.
43. Chou T-C, Talalay P. Analysis of combined drug effects: a new look at a very old problem. Trends Pharmacol Sci 1983; 4: 450-454.
44. Inoue S, Hao Z, Elia AJ, Cescon D, Zhou L, Silvester J et al. Mule/Huwe1/Arf-BP1 suppresses Ras-driven tumorigenesis by preventing c-Myc/Miz1-mediated down-regulation of p21 and p15. Gen Dev 2013; 27: 1101-1114.
45. Malatesta M, Peschiaroli A, Memmi EM, Zhang J, Antonov A, Green DR et al. The Cul4ADDB1 E3 ubiquitin ligase complex represses p73 transcriptional activity. Oncogene 2012; 32: 4721-4726.
46. Sayan BS, Yang AL, Conforti F, Tucci P, Piro MC, Browne GJ et al. Differential control of TAp73 and DeltaNp73 protein stability by the ring finger ubiquitin ligase PIR2. Proc Natl Acad Sci USA 2010; 107: 12877-12882.
47. Dulloo I, Gopalan G, Melino G, Sabapathy K. The antiapoptotic DeltaNp73 is degraded in a c-Jun-dependent manner upon genotoxic stress through the antizyme-mediated pathway. Proc Natl Acad Sci USA 2010; 107: 4902-4907.
48. Peschiaroli A, Scialpi F, Bernassola F, Pagano M, Melino G. The F-box protein FBXO45 promotes the proteasome-dependent degradation of p73. Oncogene 2009; 28: 3157-3166.
49. Munarriz E, Bano D, Sayan AE, Rossi M, Melino G, Nicotera P. Calpain cleavage regulates the protein stability of p73. Biochem Biophys Res Commun 2005; 333: 954-960.
50. Bernassola F, Salomoni P, Oberst A, Di Como CJ, Pagano M, Melino G et al. Ubiquitindependent degradation of p73 is inhibited by PML. J Exp Med 2004; 199: 1545-1557.
51. Peschiaroli A, Skaar JR, Pagano M, Melino G. The ubiquitin-specific protease USP47 is a novel beta-TRCP interactor regulating cell survival. Oncogene 2010; 29: 1384-1393.
52. Kamadurai HB, Souphron J, Scott DC, Duda DM, Miller DJ, Stringer D et al. Insights into ubiquitin transfer cascades from a structure of a UbcH5B approximately ubiquitin- HECT(NEDD4L) complex. Mol Cell 2009; 36: 1095-1102.
53. Rubinsztein DC, Gestwicki JE, Murphy LO, Klionsky DJ. Potential therapeutic applications of autophagy. Nat Rev Drug Discov 2007; 6: 304-312.
54. Scheffner M, Staub O. HECT E3s and human disease. BMC Biochem 2007; 8(Suppl 1): S6.
55. Ben-Saadon R, Zaaroor D, Ziv T, Ciechanover A. The polycomb protein Ring1B generates self atypical mixed ubiquitin chains required for its in vitro histone H2A ligase activity. Mol Cell 2006; 24: 701-711.
56. ICM Version 3.7.2 ed. MolSoft, LLC: La Jolla, CA, 2012.
57. Diaz P, Phatak SS, Xu J, Fronczek FR, Astruc-Diaz F, Thompson CM et al. 2,3-Dihydro- 1-benzofuran derivatives as a series of potent selective cannabinoid receptor 2 agonists: design, synthesis, and binding mode prediction through ligand-steered modeling. Chem Med Chem 2009; 4: 1615-1629.
58. Monti MC, Casapullo A, Cavasotto CN, Tosco A, Dal Piaz F, Ziemys A et al. The binding mode of petrosaspongiolide M to the human group IIA phospholipase A(2): exploring the role of covalent and noncovalent interactions in the inhibition process. Chem-Eur J 2009; 15: 1155-1163.
59. Phatak SS, Gatica EA, Cavasotto CN. Ligand-steered modeling and docking: A benchmarking study in Class A G-Protein-Coupled Receptors. J Chem Inf Model 2010; 50: 2119-2128.
60. Gatica EA, Cavasotto CN. Ligand and Decoy Sets for Docking to G Protein-Coupled Receptors. Journal of chemical information and modeling 2012; 52: 1-6. Federation